Efficacy and Safety of AZD1222, BNT162b2 and mRNA-1273 vaccines against SARS-CoV-2
AJTES Vol 5, No 1, January 2021
Pdf Full Text


clinical trials

How to Cite

Alimehmeti, I. (2021). Efficacy and Safety of AZD1222, BNT162b2 and mRNA-1273 vaccines against SARS-CoV-2. Albanian Journal of Trauma and Emergency Surgery, 5(1), 791-796. https://doi.org/10.32391/ajtes.v5i1.178


SARS-CoV-2, the beta coronavirus causing COVID-19, was isolated and categorizes as a novel one on January 7th, 2020 in China.[1] To date, official reports depict that SARS-CoV-2 has already infected 88.828.387 persons and caused 1.926.625 deaths worldwide.[2] On January 12th, 2020, China officials made public its genetic sequence, thus paving the way towards the research and development of diagnostic tests and vaccines.

With regard to vaccination, e large number of clinical trials were designed and are currently undergoing, of which 189 are listed in ClinicalTrials.gov. [3] However, up to date, only three vaccines have published their respective phase III clinical trial results in peer-reviewed medical journals. [4-6]

Vaccines are needed to reduce the morbidity and mortality associated with Covid-19, and multiple vaccine platforms as AZD1222 (AstraZeneca) [4], BNT162b2 (Pfizer/BioNTech) [5] and mRNA-1273 (Moderna) have been involved in the rapid development of vaccine candidates.

Methodology: In this review, PubMed, Embase, Web of Science, Scopus, medRxiv, and bioRxiv were systematically scrutinized for peer-reviewed and preprint articles on phase III clinical trials of vaccines against SARS-CoV-2. In total, only three peer-reviewed papers fulfilling the search criteria were identified.

Conclusions; All vaccine candidates should publish in peer-reviewed journals their efficacy and safety well before requesting approval to the national or international authorities…

Pdf Full Text


World Health Organization. Novel Coronavirus (2019-nCoV) Situation Report – 1. 21 January 2020. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200121-sitrep-1-2019-ncov.pdf

World Health Organization. Weekly Operational Update on COVID-19. 11 January 2020. https://www.who.int/publications/m/item/weekly-operational-update-on-covid-19---11-january-2021

https://clinicaltrials.gov/ct2/results?cond=%28covid-19+OR+Sars-Cov-2%29+AND+vaccine&term. Last accessed on January 12th, 2021.

Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet 2021; 397; 10269: 99-111, December 08, 2020 https://doi.org/10.1016/S0140-6736(20)32661-1

Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 2020; 383:2603-2615, December 10, 2020 doi: 10.1056/NEJMoa2034577

Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. December 30, 2020 doi: 10.1056/NEJMoa2035389

https://www.ema.europa.eu/en/news/ema-recommends-first-covid-19-vaccine-authorisation-eu. Last accessed on January 12th, 2021.

https://www.ema.europa.eu/en/news/ema-recommends-covid-19-vaccine-moderna-authorisation-eu. Last accessed on January 12th, 2021.

https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccine. Last accessed on January 12th, 2021.

https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/moderna-covid-19-vaccine. Last accessed on January 12th, 2021.

https://www.astrazeneca.com/media-centre/press-releases/2020/astrazenecas-covid-19-vaccine-authorised-in-uk.html. Last accessed on January 12th, 2021.

https://www.evropaelire.org/a/shqiperi-vaksinimi-covid-19-/31041855.html. Last accessed on January 12th, 2021.

Pardi N, Tuyishime S, Muramatsu H, et al. Expression kinetics of nucleosidemodified mRNA delivered in lipid nanoparticles to mice by various routes. J Control Release 2015; 217: 345-51.

Karikó K, Muramatsu H, Welsh FA, et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther 2008; 16:1833-40.

Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 2020; 367: 1260-3.

Rare Diseases Database. https://rarediseases.org/rare-diseases/transverse-myelitis/ Last accessed on January 12th, 2021.

Istituto Superiore della Sanità Gruppo della Sorveglianza SARS-CoV-2, Palmieri L, Agazio E, Andrianou X, et al. Caratteristiche dei pazienti deceduti positivi all’infezione da SARS-CoV-2 in Italia. Rapporto December 16th 2020.

https://www.pharmacist.com/article/two-uk-suffer-allergic-reaction-pfizers-covid-19-vaccine. Last accessed on January 12th, 2021.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.